Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...
Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...
Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a ...
Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...
Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true. However, dividends are paid out of cash flow, not earnings, so a payout ratio ...
Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from ...
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel ...
In the lucrative obesity drug race, there is Eli Lilly — and then there's everybody else. A pair of headlines Monday reinforced Lilly's dominance: Its lone commercial rival, Novo Nordisk , released ...
For most of the last quarter-century, the FTSE 100 has been a dead duck, effectively going sideways for a generation. But ...
The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna, accelerated a revival of Moderna shares that has been in progress over recent months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results